top of page

Renowned Physician and Longevity Expert Dr. Robert Lufkin Highlights MitoSense’s MOT™ Technology

  • Apr 20
  • 1 min read

MitoSense is proud to be featured by Dr. Robert Lufkin MD, one of the leading voices in metabolic health and longevity, in his widely read Substack and popular YouTube series.


In his recent Substack article "Can a Transplant Cure Aging? The Next Frontier in Longevity Medicine," Dr. Lufkin explores mitochondrial dysfunction as a shared upstream driver of aging and chronic diseases, including ALS, Parkinson’s, Alzheimer’s, stroke, and type 2 diabetes.


Dr. Lufkin spotlights MitoSense’s patented Mitochondria Organelle Transplantation (MOT™) as a promising approach to restore cellular energy production by delivering healthy, young mitochondria directly to damaged cells. He notes that MOT™ mitochondria, amplified from a simple donor skin biopsy, appear to evade immune rejection due to the absence of HLA antigens, cross the blood-brain barrier, and migrate to sites of metabolic distress.


In an accompanying interview on his YouTube channel, Dr. Lufkin speaks with MitoSense Chief Medical Officer Dr. Catherine Baucom MD PhD and Chairman Van Hipp about preclinical data, a compassionate-use ALS case showing notable functional improvements, and the technology’s broad therapeutic potential.


Dr. Lufkin concludes that MOT™ represents “one of the most consequential breakthroughs in modern medicine,” with potential implications far beyond any single disease.


We at MitoSense remain committed to rigorous clinical development and are grateful for Dr. Lufkin’s thoughtful coverage as we advance this technology toward broader patient benefit.




 
 
bottom of page